<DOC>
	<DOCNO>NCT01373918</DOCNO>
	<brief_summary>Neonates congenital/acquired gastrointestinal disorder high risk Parenteral Nutrition Associated Cholestasis ( PNAC ) . Besides enteral nutrition , standard therapy prevent treat PNAC limit marginal . Recently , dose composition standard intravenous fat emulsion implicate development progression PNAC . In study , neonate congenital/acquired gastrointestinal disorder randomize , unblinded fashion , receive either standard dose intravenous omega-6 fatty acid emulsion low dose intravenous omega-6 fatty acid emulsion throughout course PN hospital discharge , death 100 day life , whichever come first . The primary outcome presence cholestasis .</brief_summary>
	<brief_title>Low Dose Fat Prevention Liver Disease Babies With Gastrointestinal Disorders</brief_title>
	<detailed_description>Parenteral Nutrition ( PN ) act intravenous source macronutrients micronutrients enteral feed possible . Intravenous fat emulsion often supplement PN provide dense source non-protein calorie essential fatty acid . Although PN life-sustaining , associate myriad life-threatening complication include Parenteral Nutrition Associated Cholestasis ( PNAC ) . Children dependent PN extend period time high risk liver failure . The etiology PNAC remain poorly understood . Neonates congenital acquire gastrointestinal disorder high risk PNAC subsequent complication . Examples gastrointestinal disorder include gastroschisis , volvulus , atresia , dysmotility malabsorption disorder , pseudo-obstruction , Hirschsprung 's disease . These disorder often render gut non-functional extend period time . As result , patient become PN-dependent develop PNAC . Specific PN component implicate pathogenesis PNAC . More recently , standard intravenous fat emulsion label one main culprit contribute PNAC . Standard intravenous fat emulsion dose high 4 g/kg/d derive soybean and/or safflower oil , rich omega-6 fatty acid phytosterols contain paucity omega-3 fatty acid . It unclear dose high omega-6 fatty acid : omega-3 fatty acid ratio phytosterols responsible development PNAC . The primary specific aim study determine PNAC relate amount standard intravenous fat emulsion administer neonate congenital/acquired gastrointestinal disorder . The investigator hypothesize PNAC unrelated dose intravenous fat emulsion . To test hypothesis , neonate congenital/acquired gastrointestinal disorder randomize low dose standard soybean base parenteral fat , 1 g/kg/d , standard dose soybean parenteral fat , 3 g/kg/d . Secondary outcome include : mortality rate , length stay , anthropometric measurement 28 day life end hospital stay , expect average 5 week .</detailed_description>
	<mesh_term>Cholestasis</mesh_term>
	<mesh_term>Digestive System Diseases</mesh_term>
	<mesh_term>Gastrointestinal Diseases</mesh_term>
	<mesh_term>Soybean oil , phospholipid emulsion</mesh_term>
	<mesh_term>Fat Emulsions , Intravenous</mesh_term>
	<criteria>congenital acquire gastrointestinal disorder age le 5 day life congenital intrauterine infection know associate liver involvement know structural liver abnormality know genetic disorder ( trisomy 21 , 13 , 18 ) inborn error metabolism infant meet criterion terminal illness ( ph:6.8 &gt; 2 hour )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>5 Days</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>cholestasis</keyword>
	<keyword>neonate</keyword>
	<keyword>parenteral nutrition</keyword>
	<keyword>gastrointestinal disorder</keyword>
</DOC>